BNTC (Benitec Biopharma) 3-Year RORE % : -73.25% (As of Mar. 2026)


BNTC Benitec Biopharma Inc BNTC
34 GF Score
Price $12.92
View Full Analysis

What is Benitec Biopharma 3-Year RORE %?

Benitec Biopharma BNTC +1.97% 34 3-Year RORE % is -73.25 as of Mar. 2026. GuruFocus rates BNTC with a GF Score™ of 34/100. Among 1,294 Biotechnology companies, Benitec Biopharma ranks worse than 88.87% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Benitec Biopharma's 3-Year RORE % for the quarter that ended in Mar. 2026 was -73.25%.

The industry rank for Benitec Biopharma's 3-Year RORE % or its related term are showing as below:

BNTC's 3-Year RORE % is ranked worse than
88.87% of 1294 companies
in the Biotechnology industry
Industry Median: -11.54 vs BNTC: -73.25

Benitec Biopharma  (NAS:BNTC) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Benitec Biopharma 3-Year RORE % Related Terms


Benitec Biopharma 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma 3-Year RORE % Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -39.30 -45.83 -52.60 -65.86

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.32 -65.86 -66.75 -77.29 -73.25

BNTC vs IPSC, FBRX, AUTL: 3-Year RORE % Comparison

For the Biotechnology subindustry, Benitec Biopharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's 3-Year RORE % falls into.


BNTC
34GF Score
Benitec Biopharma Inc BNTC
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma 3-Year RORE % Calculation

Benitec Biopharma's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.93--8.57 )/( -10.43-0 )
=7.64/-10.43
=-73.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -73.25 mean?
Benitec Biopharma (BNTC) has a 3-Year RORE % of -73.25 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Benitec Biopharma and its competitors. According to the industry distribution chart, Benitec Biopharma ranks #1150 out of 1294 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Benitec Biopharma's 3-Year RORE % too high?
Benitec Biopharma's current 3-Year RORE % is -73.25. Based on the distribution chart, Benitec Biopharma ranks #1150 out of 1294 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's 3-Year RORE % compare to IPSC and FBRX?
According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #1150 out of 1294 companies for 3-Year RORE %. This places Benitec Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Benitec Biopharma and its competitors. Benitec Biopharma's current 3-Year RORE % is -73.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current 3-Year RORE % of -73.25. The current 3-Year RORE % is -73.25. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current 3-Year RORE % is -73.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for BNTC

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.92
Price